18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

Reproducibility of 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

In the current study, the investigators plan to expand the knowledge of Positron Emission Tomography/Magnetic Resonance (PET/MR) reliability by assessing the repeatability of fludeoxyglucose (FDG) standardized uptake values (SUV) measurements, as well as apparent diffusion coefficients (ADC) measurements, in a broad population of patients with malignant solid tumors.

Inclusion Criteria:

• Patients with histologically confirmed malignant solid tumors (local or metastatic, newly diagnosed or recurrent disease).
• Patient must have at least one lesion measuring ≥ 2.0 cm.
• 18 years of age or older.
• Ability to provide informed consent.

Exclusion Criteria:

• Cancer therapy within 30 days of baseline imaging.
• Uncontrolled intercurrent illness including, but not limited to active infections.
• Patients with insulin-dependent diabetes.
• Patients with metal devices in the body including, but not limited to metallic joint prostheses, artificial heart valves, pacemakers, and cochlear implants.
• Patients who are pregnant or nursing.
• Inability to tolerate 60 minutes of PET imaging.
• Inability to comply with study procedures.